334 related articles for article (PubMed ID: 37395506)
1. Management of patients with idiopathic pulmonary fibrosis and lung cancer: challenges in clinical practice.
Karampitsakos T; Sampsonas F; Herazo-Maya JD; Tzouvelekis A
Curr Opin Pulm Med; 2023 Sep; 29(5):416-426. PubMed ID: 37395506
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K; Kishimoto J; Ando M; Kenmotsu H; Minegishi Y; Horinouchi H; Kato T; Ichihara E; Kondo M; Atagi S; Tamiya M; Ikeda S; Harada T; Takemoto S; Hayashi H; Nakatomi K; Kimura Y; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakagawa K; Nakanishi Y; Okamoto I
Eur Respir J; 2022 Dec; 60(6):. PubMed ID: 35361630
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Yamamoto Y; Yano Y; Kuge T; Okabe F; Ishijima M; Uenami T; Kanazu M; Akazawa Y; Yamaguchi T; Mori M
Thorac Cancer; 2020 Nov; 11(11):3317-3325. PubMed ID: 32986306
[TBL] [Abstract][Full Text] [Related]
4. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
Shiratori T; Tanaka H; Tabe C; Tsuchiya J; Ishioka Y; Itoga M; Taima K; Takanashi S; Tasaka S
Thorac Cancer; 2020 Jun; 11(6):1720-1723. PubMed ID: 32285615
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
6. Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.
Bargagli E; Bonti V; Ferrari K; Rosi E; Bindi A; Bartolucci M; Chiara M; Voltolini L
In Vivo; 2017; 31(4):773-777. PubMed ID: 28652456
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
8. Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer.
Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Respirology; 2017 Oct; 22(7):1379-1385. PubMed ID: 28543987
[TBL] [Abstract][Full Text] [Related]
9. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
[TBL] [Abstract][Full Text] [Related]
10. Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation.
Koyama N; Iwai Y; Nagai Y; Aoshiba K; Nakamura H
PLoS One; 2019; 14(8):e0221718. PubMed ID: 31442290
[TBL] [Abstract][Full Text] [Related]
11. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.
Kou W; Li B; Shi Y; Zhao Y; Yu Q; Zhuang J; Xu Y; Peng W
BMC Cancer; 2022 Jan; 22(1):110. PubMed ID: 35078421
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe.
Karampitsakos T; Spagnolo P; Mogulkoc N; Wuyts WA; Tomassetti S; Bendstrup E; Molina-Molina M; Manali ED; Unat ÖS; Bonella F; Kahn N; Kolilekas L; Rosi E; Gori L; Ravaglia C; Poletti V; Daniil Z; Prior TS; Papanikolaou IC; Aso S; Tryfon S; Papakosta D; Tzilas V; Balestro E; Papiris S; Antoniou K; Bouros D; Wells A; Kreuter M; Tzouvelekis A
Respirology; 2023 Jan; 28(1):56-65. PubMed ID: 36117239
[TBL] [Abstract][Full Text] [Related]
13. Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis.
Ikeda S; Ogura T; Kato T; Kenmotsu H; Iwasawa T; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920923431. PubMed ID: 32489433
[TBL] [Abstract][Full Text] [Related]
14. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
[TBL] [Abstract][Full Text] [Related]
15. Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study.
Makiguchi T; Tanaka H; Okudera K; Taima K; Tasaka S
Transl Lung Cancer Res; 2023 Apr; 12(4):719-726. PubMed ID: 37197621
[TBL] [Abstract][Full Text] [Related]
16. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
Kanaji N; Tadokoro A; Kita N; Murota M; Ishii T; Takagi T; Watanabe N; Tojo Y; Harada S; Hasui Y; Kadowaki N; Bandoh S
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1855-65. PubMed ID: 27350261
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Ballester B; Milara J; Cortijo J
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
[TBL] [Abstract][Full Text] [Related]
18. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis].
Kolek V; Vašáková M; Šterclová M; Cwiertka K; Vrána D; Kudláček A; Skřičková J; Pešek M; Petera J
Klin Onkol; 2017; 30(4):303-306. PubMed ID: 28832178
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer in patients with idiopathic pulmonary fibrosis.
Karampitsakos T; Tzilas V; Tringidou R; Steiropoulos P; Aidinis V; Papiris SA; Bouros D; Tzouvelekis A
Pulm Pharmacol Ther; 2017 Aug; 45():1-10. PubMed ID: 28377145
[TBL] [Abstract][Full Text] [Related]
20. Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review.
Grodkiewicz M; Koziel P; Chmielewska I; Korbel MA; Milanowski J
Curr Oncol; 2022 Jul; 29(7):5077-5083. PubMed ID: 35877261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
